← All organizations
First clinical trial
Apr 1, 2001Last known activity
Jun 28, 2018
Acquired by Oncternal Therapeutics on Jun 1, 2019
Timeline
1990s
- Jun 1, 1997
GTx— Founded
2010s
- Jun 1, 2019
Oncternal Therapeutics— Acquired By
Drugs by trial phase (5 distinct, 22 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Indications
Studied for
- Blindness
- Breast Neoplasms
- Cachexia
- Carcinoma in Situ
- Carcinoma, Non-Small-Cell Lung
- Enuresis
- Fractures, Bone
- Leber Congenital Amaurosis
- Lung Neoplasms
- Muscular Atrophy
- Neoplasms
- Osteoporosis
- Precancerous Conditions
- Prostatic Intraepithelial Neoplasia
- Prostatic Neoplasms
- Triple Negative Breast Neoplasms
- Urinary Incontinence
- Urinary Incontinence, Stress
- Wasting Syndrome
Recent trials (27)
- NCT03566290Lead sponsorPhase 2Jun 28, 2018
- NCT03508648Lead sponsorPhase 2May 28, 2018
- NCT03241342Lead sponsorPhase 2Aug 21, 2017
- NCT03264651CollaboratorPhase 1Feb 1, 2017
- NCT02946879Lead sponsorPhase 1/Phase 2Nov 1, 2016
- NCT02781480Lead sponsorPhase 1Apr 1, 2016
- NCT02746328Lead sponsorPhase 2Apr 1, 2016
- NCT02658448Lead sponsorPhase 2Jan 1, 2016
- NCT02463032Lead sponsorPhase 2Aug 1, 2015
- NCT02368691Lead sponsorPhase 2Jun 1, 2015
- NCT01616758Lead sponsorPhase 2Apr 1, 2013
- NCT01615120Lead sponsorPhase 2Jul 1, 2012
- NCT01420861Lead sponsorPhase 2Sep 1, 2011
- NCT01420861Study directorPhase 2Sep 1, 2011
- NCT01393119Lead sponsorPhase 2Aug 1, 2011
Details
- Founded
- Memphis, TN, US Jun 1, 1997
- Last known activity
- Jun 28, 2018